MDL 19,205

Known as: MDL 19205, MDL-19,205, MDL-19205 
 

Topic mentions per year

Topic mentions per year

1983-1988
024619831988

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
This study compares the effects of piroximone (MDL 19,205), a new inotropic agent, with dobutamine in dogs with congestive heart… (More)
Is this relevant?
1986
1986
In isolated canine ventricular trabeculae and papillary muscles driven electrically at 0.5 Hz at 37 degrees C, the positive… (More)
Is this relevant?
1986
1986
Piroximone (MDL 19,205), a new phosphodiesterase inhibitor with positive inotropic and vasodilating properties, was administered… (More)
Is this relevant?
1986
1986
Piroximone (MDL 19,205), a new imidazolone derivative, was given intravenously to 14 patients with congestive heart failure (NYHA… (More)
Is this relevant?
1986
1986
The cardiac and coronary vasodilator effects of MDL 17043 and MDL 19205 were compared in isolated, blood-perfused papillary… (More)
  • figure 2
  • figure 3
  • figure 5
  • figure 7
  • figure 10
Is this relevant?
1984
1984
Various in vitro and in vivo techniques were used to evaluate the cardiovascular actions of MDL 19205, a new cardiotonic agent… (More)
Is this relevant?
1984
1984
The cardiovascular properties of a new cardiotonic agent, MDL 19205, were investigated in anesthetized and conscious dogs and in… (More)
Is this relevant?
1984
1984
The hemodynamic and neurohumoral effects of cummulative intravenous doses of piroximone (MDL 19205), a noncatecholamine… (More)
Is this relevant?
1984
1984
MDL 19205, 4-ethyl-1,3-dihydro-5-(4-pyridinyl-carbonyl)-2H-imidazol-2-one, is a new drug with cardiotonic properties. Its effects… (More)
Is this relevant?
1983
1983
A high-performance liquid chromatographic method has been developed for the analysis of plasma and urine concentrations of a new… (More)
Is this relevant?